aTyr Pharma, Inc. (FRA:471A)
Germany · Delayed Price · Currency is EUR | Market Cap | 14.38M -82.4% |
| Revenue (ttm) | 166.31K -19.1% |
| Net Income | -53.22M |
| EPS | -0.56 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,000 |
| Open | 0.0724 |
| Previous Close | 0.0528 |
| Day's Range | 0.0720 - 0.0724 |
| 52-Week Range | 0.0528 - 0.8000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About aTyr Pharma
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn... [Read more]
Financial Performance
In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
aTyr Pharma, Albert Einstein College of Medicine enter ATYR2810 pact
aTyr Pharma (ATYR) announced a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810, the company’s monoclonal antibody that targets the ne...
aTyr Pharma Announces Research Collaboration with Montefiore Einstein
SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...
aTyr Pharma publishes ATYR0101 data in Journal of Biological Chemistry
aTyr Pharma (ATYR) announced a publication demonstrating the anti-fibrotic effects of ATYR0101 in the Journal of Biological Chemistry. ATYR0101 is a fusion protein derived from a proprietary extracell...
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
Findings highlight ATYR0101's potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advan...
Ethos to Announce Third Quarter 2026 Financial Results on November 2, 2026
AUSTIN, Texas, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announc...
Two stock picks from a money manager who expects small caps to roar in 2027
Calamos Investments manager Brandon Nelson's four-star fund is betting on financial services apps.
Why is aTyr Pharma Stock (ATYR) Down 7% Today?
Shares in biopharmaceutical firm aTyr Pharma ($ATYR) dropped 7% today despite hopes that a trial for its lung disease drug efzofitimod was back on track. Its shares had rocketed over…
aTyr Pharma announces alignment with FDA on Phase 3 study of efzofitimod
aTyr Pharma (ATYR) announced that it has reached alignment with the U.S. FDA on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with…
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activit...
Ethos CEO Peter Collis on 113% Growth and Reinventing Life Insurance
Austin Hankwtiz is joined by Peter Collis, co-founder and CEO of Ethos Technologies, to discuss how the company is transforming life insurance with instant online underwriting, why eight of nine life ...
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...
aTyr Pharma Proxy statement: Proxy filing
aTyr Pharma filed a proxy statement on August 31, 2026, providing details for shareholder voting and corporate governance matters.
Ethos to Present at the Goldman Sachs Communacopia + Technology Conference
AUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder ...
Ethos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every Family
AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it has sig...
aTyr Pharma reports Q2 EPS (11c), consensus (13c)
Cash, cash equivalents, restricted cash and available-for-sale investments as of June 30, 2026, were $58.9 million. Based on its current cash and new operating expense forecast and plans, the Company…
aTyr Pharma announces restructuring, will lay off roughly 60% of workforce
aTyr Pharma (ATYR) announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease, including pulmonary sarcoidosis and systemic ...
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately...
aTyr Pharma Quarterly report: Q2 2026
aTyr Pharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
aTyr Pharma Earnings release: Q2 2026
aTyr Pharma released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Ethos Reports Second Quarter Fiscal Year 2026 Financial Results
Q2 Revenue grew 113 % year-over-year to $ 190 million Q2 Direct Channel Revenue grew 131 % year-over-year to $ 116 million Q2 Third-Party Revenue grew 90 % year-over-year to $ 73 million Board of Dire...
Ethos and North American Expand Their Indexed Universal Life Product Offering to include Children
AUSTIN, Texas and DES MOINES, Iowa, July 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the expan...
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to F...
Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026
AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announc...
aTyr Pharma Transcript: Life Sciences Virtual Investor Forum
Revised summary: Efzofitimod showed quality of life improvements and a strong safety profile in pulmonary sarcoidosis, despite missing the primary steroid reduction endpoint. The next phase III trial will target a sicker population with forced vital capacity as the primary endpoint, aiming for approval and expansion to other interstitial lung diseases.